ONS Publishes Manual on Psychosocial Aspects of Oncology Care
The Oncology Nursing Society (ONS) announces the publication of Psychosocial Dimensions of Oncology Nursing Care. The module, which will be available in early 1998, addresses the psychosocial aspects that affect the patient with cancer and provides practical interventions.
The Oncology Nursing Society (ONS) announces the publication of Psychosocial Dimensions of Oncology Nursing Care. The module, which will be available in early 1998, addresses the psychosocial aspects that affect the patient with cancer and provides practical interventions.
The module is designed as a broad overview of common psychosocial concerns in cancer care and provides a review of assessment techniques and practical strategies to assist patients, families, and caregivers. The major subject headings include:
- Coping with cancer;
- Patient and family issues;
- Spirituality;
- Survivorship;
- Sexuality;
- Body image;
- Death, dying, and bereavement;
- Alterative therapies; and
- Self-care for nurses.
Within each of these subject headings are detailed and specific strategies and suggestions for dealing with the day-to-day problems faced by patients and their families.
The manual can be purchased for $15 (ONS member) and $18 (nonmember). To order the manual, contact: ONS Customer Service Department, 501 Holiday Drive, Pittsburgh, PA 15220, or call (412) 921-7373.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
![“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F7d7dfad7849391f4be3ebd2cf39c24f5369cfcd1-1200x1176.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).")
